These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16598396)

  • 1. Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation.
    Obergassel L; Lawrenz T; Gietzen FH; Lieder F; Leuner C; Kuhn H; Stellbrink C
    Clin Res Cardiol; 2006 May; 95(5):254-60. PubMed ID: 16598396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transcoronary ablation of septal hypertrophy versus dual-chamber cardiac pacing for the treatment of aged patients with hypertrophic obstructive cardiomyopathy].
    Gao YC; Li Y; Han ZH; Zhang XL; Zhao H; Jiang TY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Apr; 35(4):333-6. PubMed ID: 17711659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent atrial flutter after radiofrequency ablation for atrial fibrillation in a patient with hypertrophic obstructive cardiomyopathy undergoing repetitive transcoronary ablation of septal hypertrophy.
    Cheng L; Wang N; Dai L; Ding H; Geng Z; Son Y
    BMC Cardiovasc Disord; 2024 Oct; 24(1):532. PubMed ID: 39358714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.
    Kuhn H; Lawrenz T; Lieder F; Leuner C; Strunk-Mueller C; Obergassel L; Bartelsmeier M; Stellbrink C
    Clin Res Cardiol; 2008 Apr; 97(4):234-43. PubMed ID: 18071624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy.
    Kuhn H; Gietzen FH; Leuner C; Schäfers M; Schober O; Strunk-Müller C; Obergassel L; Freick M; Gockel B; Lieder F; Raute-Kreinsen U
    Z Kardiol; 2000; 89 Suppl 4():IV41-54. PubMed ID: 10810776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term outcomes of transcoronary ablation of septal hypertrophy compared to surgical myectomy in patients with symptomatic hypertrophic obstructive cardiomyopathy.
    Samardhi H; Walters DL; Raffel C; Rateesh S; Harley C; Burstow D; Pohlner P; Aroney C
    Catheter Cardiovasc Interv; 2014 Feb; 83(2):270-7. PubMed ID: 23873660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of atrial fibrillation in hypertrophic cardiomyopathy.
    Guttmann OP; Pavlou M; O'Mahony C; Monserrat L; Anastasakis A; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; Garcia-Pavia P; McKenna WJ; Omar RZ; Elliott PM;
    Heart; 2017 May; 103(9):672-678. PubMed ID: 27794017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Transcoronary ablation of septal hypertrophy (TASH): a 5-year experience].
    Kuhn H
    Z Kardiol; 2000 Jun; 89(6):559-64. PubMed ID: 10929441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry.
    Kuhn H; Seggewiss H; Gietzen FH; Boekstegers P; Neuhaus L; Seipel L
    Z Kardiol; 2004 Jan; 93(1):23-31. PubMed ID: 14740238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Rowin EJ; Link MS; Maron MS; Maron BJ
    Circulation; 2023 Nov; 148(22):1797-1811. PubMed ID: 38011245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: atrial fibrillation type determines the success rate.
    Derejko P; Polańska M; Chojnowska L; Michałowska I; Wójcik A; Piotrowicz E; Lech A; Kłopotowski M; Baranowski R; Przybylski A; Bilińska M; Sierpiński R; Walczak F; Szumowski L
    Kardiol Pol; 2013; 71(1):17-24. PubMed ID: 23348529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy.
    Kilicaslan F; Verma A; Saad E; Themistoclakis S; Bonso A; Raviele A; Bozbas H; Andrews MW; Beheiry S; Hao S; Cummings JE; Marrouche NF; Lakkireddy D; Wazni O; Yamaji H; Saenz LC; Saliba W; Schweikert RA; Natale A
    Heart Rhythm; 2006 Mar; 3(3):275-80. PubMed ID: 16500298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M; Dokainish H; Lakkis N
    J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Lieder F; Bartelsmeier M; Leuner C; Borchert B; Meyer zu Vilsendorf D; Strunk-Mueller C; Reinhardt J; Feuchtl A; Stellbrink C; Kuhn H
    J Am Coll Cardiol; 2007 Jun; 49(24):2356-63. PubMed ID: 17572252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device.
    Wilke I; Witzel K; Münch J; Pecha S; Blankenberg S; Reichenspurner H; Willems S; Patten M; Aydin A
    J Cardiovasc Electrophysiol; 2016 Jul; 27(7):779-84. PubMed ID: 27060297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.
    Sohns C; Sossalla S; Schmitto JD; Jacobshagen C; Raab BW; Obenauer S; Maier LS
    Clin Res Cardiol; 2010 Jun; 99(6):359-68. PubMed ID: 20503122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy.
    Gietzen FH; Leuner CJ; Raute-Kreinsen U; Dellmann A; Hegselmann J; Strunk-Mueller C; Kuhn HJ
    Eur Heart J; 1999 Sep; 20(18):1342-54. PubMed ID: 10462469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Rowin EJ; Hausvater A; Link MS; Abt P; Gionfriddo W; Wang W; Rastegar H; Estes NAM; Maron MS; Maron BJ
    Circulation; 2017 Dec; 136(25):2420-2436. PubMed ID: 28916640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety and efficacy comparison of myocardial contrast enhancement-guided and angio-pressure-guided transcoronary ablation of septal hypertrophy for patients with hypertrophic obstructive cardiomyopathy].
    Gao YC; Li Y; Wu XS; Jia CQ; Jiang TY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jun; 35(6):540-3. PubMed ID: 17711715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.